Key result
Melatonin improves quality of life and NYHA class in heart failure without boosting ejection fraction.
Why the study?
Melatonin therapy is a less-known and rarely used treatment method for heart failure patients despite the high incidence and prevalence of heart failure.
Does melatonin therapy improve cardiac function and quality of life in heart failure patients?
Meta-Analysis
Does melatonin therapy improve cardiac function and quality of life in heart failure patients?
Melatonin therapy may improve quality of life and NYHA functional class in patients with heart failure, though its effect on ejection fraction was not statistically significant.
May support adjunctive melatonin to improve HF outcomes; extends meta-analytic evidence for its cardiac benefits.
BACKGROUND: Heart failure as an advanced cardiac disease has a high incidence and prevalence in all societies nowadays. Many drugs and treatment methods have been discovered for improving heart failure patients' conditions till now in this way melatonin therapy is one of the less-known methods rarely used by clinicians. METHODS: To investigate the positive effect of melatonin on heart failure development, we conducted a systematic review and meta-analysis by searching valid databases with keywords based on the protocol. Based on the eligible criteria, four articles were selected for data synthesis and analysis after scanning the title and/or abstract and reading full-text. RESULTS: As a result of analysis, increasing ejection fraction (Mean difference: 2.39 [-1.82, 6.59] p = 0.27), NYHA (New York Heart Association Functional Class) (Odds ratio: 4.84 [1.00, 23.44] p = 0.05), and significant elevation of quality of life (Mean difference: -5.95 [-9.54, -2.35] p = 0.001) were observed. As the effect of melatonin, fatigue, and NT-Pro BNP were reduced but on the contrary sleep quality, appetite, and FMD (Flow-Mediated Dilation) significantly increased. CONCLUSION: Thus, melatonin, by increasing psychologic parameters and cardiac potency, could be advised as a novel drug for treatment and palliating heart failure patients.
No takes yet. Share an insight, caveat, or question.
Daliri et al. (2025) conducted a meta-analysis in Heart failure. Melatonin was evaluated on Quality of life (MD -5.95, 95% CI -9.54 to -2.35, p=0.001). Melatonin therapy significantly improved quality of life (MD -5.95; 95% CI -9.54 to -2.35; p=0.001) and NYHA class in heart failure patients, but did not significantly increase ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: